PATENT CLAIM ANALYSIS

Application Number: 16173114
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["424", "136100"]

Abstract:
Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

Claim (Index 108):
A method of promoting the specific lysis of target cells expressing an antigen of interest which is specifically bound by a therapeutic antibody or therapeutic antigen-binding antibody fragment in a subject in need thereof, comprising contacting said target cells with an amount of a multispecific antigen binding protein which is sufficient to promote the specific lysis of said target cells expressing said antigen of interest, wherein said multispecific antigen binding protein comprises:\n (i) a first antigen binding domain (ABD) which monovalently binds to a human NKp46 polypeptide having the amino acid sequence set forth in SEQ ID NO:1, (ii) a second ABD which comprises a therapeutic antibody or a therapeutic antigen-binding antibody fragment which binds to said antigen of interest expressed by target cells, and (iii) a CD16A binding polypeptide, wherein:\n (1) said NKp46-binding ABD comprises a Fab or comprises a V H  chain domain and a V L  chain domain separated by a linker (\u201cscFv\u201d); \n (2) said cancer-antigen-binding ABD, which comprises said therapeutic antibody or therapeutic antigen-binding antibody fragment, is monovalent or bivalent; \n (3) said CD16A binding polypeptide comprises a dimeric human Fc domain polypeptide which binds CD16A; \n (4) said multispecific antigen binding protein binds to the NKp46 polypeptide monovalently; \n (5) said multispecific antigen binding protein directs NKp46-expressing NK cells and CD16A-expressing NK cells to lyse target cells expressing the antigen of interest by a combination of NKp46-mediated signaling and CD16A-mediated ADCC; \n (6) said dimeric Fc domain interposes said first ABD and said second ABD; \n (7) said first and second ABD are each attached to said dimeric Fc domain, and wherein one or both of said first and second ABD are connected to the Fc domain via a flexible polypeptide linker.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 97.0
- Lexical Diversity: 1.31429
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15190337', '15321650', '14691509', '16041309', '11921123']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7557284008409231
- 35 USC 102 Novelty (BERT): 0.7603766338000039
- Combined Prediction Score: 0.7561932241368312
- Mean Citation Score: 535.968584
- Max Citation Score: 918.7742
- Similarity Product: 869.5639248927235

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test